SPAC1348.04 Antibody

What is the SPAC1348.04 antibody and what cellular structures does it target?

SPAC1348.04 antibody is a research tool designed to target specific protein epitopes. While detailed information about this specific antibody is limited in the available research, antibodies generally function by recognizing and binding to specific antigens. Similar to highly specific antibodies like those targeting Staphylococcus aureus protein A (SpA5) or oligodendrocyte marker O4, SPAC1348.04 antibody would recognize a unique epitope structure .

The methodology for identifying target structures typically involves:

• Immunocytochemistry (ICC) for cellular localization

• Western blotting for molecular weight confirmation

• Immunoprecipitation for protein complex identification

When working with novel antibodies, researchers should validate specificity using multiple techniques and appropriate controls to ensure accurate target identification.

What are the recommended protocols for SPAC1348.04 antibody storage and reconstitution?

While specific storage information for SPAC1348.04 antibody isn't detailed in the search results, general antibody preservation principles apply. Based on established protocols for research-grade antibodies, the following guidelines should be considered:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain antibody integrity

• Long-term storage: -20°C to -70°C for approximately 12 months from receipt date

• Short-term storage: 2-8°C under sterile conditions after reconstitution (typically stable for 1 month)

• Extended storage after reconstitution: -20°C to -70°C under sterile conditions (stable for approximately 6 months)

For reconstitution, sterile techniques are essential. Most antibodies benefit from reconstitution in sterile PBS containing a carrier protein (often BSA) at concentrations between 0.1-1.0%. Document reconstitution date and resulting concentration directly on the vial for tracking purposes.

What dilution ranges are appropriate for different applications of SPAC1348.04 antibody?

Optimal dilutions for antibody applications must be empirically determined for each specific use case. As seen with other research antibodies, dilution requirements vary significantly between applications:

Each laboratory should determine optimal conditions through systematic dilution series testing. As demonstrated with the O4 antibody application, protocols often specify concentrations in μg/mL rather than dilution factors for reproducibility across different antibody preparations .

How can SPAC1348.04 antibody be validated for cross-reactivity across different species?

Cross-reactivity validation requires systematic experimental design across multiple species. Based on approaches used for other antibodies like the O4 marker antibody (which shows reactivity across human, mouse, rat, and chicken species), researchers should:

• Perform sequence homology analysis of the target protein across species using bioinformatic tools

• Test antibody binding against recombinant proteins from each species of interest

• Validate in cellular contexts from each species using appropriate controls:

  • Positive controls: Cells known to express the target

  • Negative controls: Knockout/knockdown cells or tissues

  • Pre-absorption controls: Pre-incubating antibody with purified antigen

Researchers should document binding patterns in each species, noting any differences in sensitivity or background. When publishing cross-reactivity data, include detailed methodological descriptions and representative images from each species to facilitate reproducibility .

What are the approaches for epitope mapping of SPAC1348.04 antibody binding sites?

Epitope mapping represents a critical advanced technique for characterizing antibody-antigen interactions. Based on approaches used with antibodies like Abs-9 against SpA5, several complementary methods can be employed:

• Computational prediction and molecular docking:

  • Use AlphaFold2 or similar tools to generate 3D structural models of both antibody and target

  • Employ molecular docking software (e.g., Discovery Studio) to predict binding interfaces

  • Identify potential epitope residues through energetic analysis of the complex

• Experimental validation of predicted epitopes:

  • Synthesize peptides corresponding to predicted epitope regions

  • Couple to carrier proteins (e.g., keyhole limpet hemocyanin) for detection

  • Test binding by ELISA or other immunoassays

  • Perform competitive binding assays between synthetic peptides and full-length antigen

• Mutational analysis:

  • Generate point mutations at predicted interface residues

  • Express mutant proteins and test for altered antibody binding

The study by Zhou et al. demonstrated this comprehensive approach by identifying a specific epitope (N847-S857) on SpA5 that bound to their antibody Abs-9, validated through both computational predictions and experimental verification .

How can SPAC1348.04 antibody be employed in high-throughput screening applications?

High-throughput screening (HTS) with antibodies requires optimization of assay conditions for reliability, sensitivity, and reproducibility at scale. Based on approaches used in antibody research:

• Assay development considerations:

  • Minimize protocol steps to reduce variability and increase throughput

  • Optimize signal-to-noise ratio through careful blocking and washing procedures

  • Develop appropriate positive and negative controls for each plate

  • Validate Z-factor scoring to ensure assay robustness

• Screening platform options:

  • Microplate-based ELISA: Suitable for target protein quantification across many samples

  • Cell-based imaging: For subcellular localization or expression patterns

  • Flow cytometry: For population analysis when combined with other markers

• Data analysis and validation pipeline:

  • Develop automated image analysis workflows if using high-content imaging

  • Implement statistical methods for hit identification with appropriate thresholds

  • Establish secondary validation assays for confirmation of primary hits

The approach demonstrated in the high-throughput single-cell sequencing study of B cells from vaccine volunteers represents how antibody-related research can be scaled effectively, with 676 antigen-binding clonotypes identified and characterized .

What are common causes of high background when using SPAC1348.04 antibody in immunocytochemistry?

High background in immunocytochemistry represents a common challenge that can obscure specific signals. Based on established antibody protocols:

• Primary causes of high background:

  • Insufficient blocking: Extend blocking time or use alternative blocking agents

  • Excessive antibody concentration: Titrate the antibody to determine optimal dilution

  • Inadequate washing: Increase wash duration and volume between steps

  • Fixation artifacts: Test different fixation methods (PFA, methanol, acetone)

  • Non-specific binding: Add carrier proteins to antibody diluent (BSA, normal serum)

• Optimization approach:

  • Systematic variable testing: Change one parameter at a time

  • Include appropriate controls: Secondary-only, isotype controls, known negative tissues

  • Consider antigen retrieval modifications if working with fixed tissues

• Advanced troubleshooting:

  • Pre-adsorption: Incubate antibody with recombinant antigen before staining

  • Cross-adsorption: Pre-incubate with related proteins to remove cross-reactive antibodies

  • Try different detection systems: Direct vs. indirect labeling approaches

The protocols used for O4 antibody staining in differentiated rat cortical stem cells demonstrate careful optimization, with specific parameters like incubation times (3 hours at room temperature) and concentrations (1 μg/mL) that yielded clean staining with minimal background .

What strategies can improve signal detection when working with low-abundance targets?

Detecting low-abundance proteins requires specialized approaches to amplify signal while maintaining specificity:

• Signal amplification methods:

  • Tyramide signal amplification (TSA): Can increase sensitivity 10-100 fold

  • Poly-HRP secondary antibodies: Multiple HRP molecules per binding event

  • Biotin-streptavidin systems: Exploits high-affinity interaction for signal enhancement

  • Nanobody-based detection: Smaller size enables better tissue penetration

• Sample preparation optimization:

  • Antigen retrieval: Test different methods (heat-induced, enzymatic)

  • Permeabilization: Adjust detergent concentration and exposure time

  • Reduce autofluorescence: Using specific quenching agents appropriate for tissue type

• Imaging considerations:

  • Confocal microscopy with increased laser power and detector gain

  • Extended exposure times balanced against photobleaching

  • Deconvolution algorithms for improved signal-to-noise ratio

  • Super-resolution techniques for detecting discrete molecular targets

• Controls for validation:

  • Positive control samples with known expression

  • Overexpression systems to confirm antibody functionality

  • RNA expression correlation (ISH or RNA-seq) to confirm protein detection patterns

The O4 antibody staining protocols demonstrate several of these approaches, with careful counterstaining using DAPI and optimization of detection parameters for visualization of oligodendrocyte markers in neural stem cells .

How can SPAC1348.04 antibody be incorporated into multicolor flow cytometry panels?

Designing effective multicolor flow cytometry panels requires careful consideration of fluorophore selection, antibody performance, and panel validation:

• Panel design principles:

  • Spectral compatibility: Select fluorophores with minimal spectral overlap

  • Brightness matching: Pair dim markers with bright fluorophores and vice versa

  • Marker co-expression: Consider which markers need to be clearly distinguished

  • Titration for each antibody: Determine optimal concentration for specific signal

• Compensation and controls:

  • Single-stained controls for each fluorophore in the panel

  • Fluorescence-minus-one (FMO) controls to set accurate gates

  • Isotype controls matched to each antibody's isotype and concentration

• Practical implementation:

  • Begin with existing validated panels and add new antibodies incrementally

  • Test conjugation chemistry if directly labeling SPAC1348.04 antibody

  • Validate panel performance with known positive and negative populations

The flow cytometry application of the O4 antibody in rat cortical stem cells demonstrates how antibodies can be effectively incorporated into flow cytometry workflows for detection of specific cellular populations, with careful attention to secondary antibody selection (PE-conjugated Anti-Mouse IgM) to enable proper detection .

What approaches enable co-localization studies between SPAC1348.04 and other cellular markers?

Co-localization studies provide crucial insights into protein interactions and cellular functions:

The co-staining protocol used for Olig2 and O4 markers in rat cortical stem cells demonstrates effective co-localization methodology, with distinct fluorophores (NorthernLights 637 for Olig2 and a separate fluorophore for O4) enabling clear visualization of both markers simultaneously .

How can SPAC1348.04 antibody be adapted for use in organoid and 3D culture systems?

Three-dimensional culture systems present unique challenges for antibody penetration and detection:

• Optimization for 3D tissue penetration:

  • Extended incubation times (24-72 hours for primary antibodies)

  • Increased antibody concentrations (typically 2-5× higher than for 2D cultures)

  • Enhanced permeabilization protocols specific to organoid type and size

  • Clearing techniques to improve optical transparency (CLARITY, Scale, etc.)

• Validation approaches:

  • Sectioning of parallel samples to confirm complete penetration

  • Z-depth analysis of signal intensity to assess penetration uniformity

  • Comparison with mRNA expression (RNA-FISH) for target validation

• Imaging considerations:

  • Light-sheet microscopy for rapid imaging of intact organoids

  • Long working-distance objectives for thick specimen imaging

  • Computational approaches for dealing with light scattering and signal attenuation

Recent applications of antibodies in cerebral organoids, as referenced in the citations for the O4 antibody, demonstrate the adaptability of antibody techniques to complex 3D culture systems, requiring significant protocol modifications compared to traditional 2D methods .

What considerations are important when using SPAC1348.04 antibody for in vivo imaging applications?

In vivo imaging with antibodies presents unique challenges requiring specialized approaches:

• Antibody modification requirements:

  • Fluorophore selection for in vivo imaging (far-red and NIR for tissue penetration)

  • Consideration of antibody half-life and clearance kinetics

  • Potential for immunogenicity if used in longitudinal studies

  • Fragment development (Fab, scFv) for improved tissue penetration

• Delivery optimization:

  • Local vs. systemic administration routes

  • Blood-brain barrier considerations for CNS targets

  • Dosing optimization to balance signal intensity and background

  • Timing of imaging relative to antibody administration

• Imaging modalities:

  • Intravital microscopy for high-resolution cellular imaging

  • Whole-animal fluorescence imaging for anatomical distribution

  • Potential for antibody-based PET imaging with appropriate modifications

• Controls and validation:

  • Non-specific isotype controls with matched modification

  • Blocking studies to confirm specificity in vivo

  • Ex vivo validation of in vivo findings

The prophylactic efficacy testing of the Abs-9 antibody against S. aureus infection in mice demonstrates how antibodies can be effectively utilized in vivo, with careful consideration of dosing, timing, and specificity validation .